Search Bar & Filters
Found 39 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying osivelotor, an oral drug, in adults and adolescents with sickle cell disease SCD. This Phase 23 trial aims to evaluate the safety, tolerability, effectiveness, and how the body processes the drug. The study includes participants with specific SCD types and looks to find the best dose while also comparing the drug against a placebo over 48 weeks. A long-term extension will assess ongoing safety and blood response. The study has three parts. Part A tested safety and dose in adults to find the optimal dose. Part B compares osivelotor to placebo in adults and adolescents over 48 weeks, with adults receiving a loading dose of 300 mg daily for 7 days then 150 mg daily, while adolescent doses will be defined later. An open-label extension allows participants who completed Part B to take osivelotor for up to two years or until it becomes commercially available. Participants will undergo screening to confirm eligibility, including stable hemoglobin levels and SCD history. During the trial, participants receive study medication or placebo and attend regular visits for monitoring. Researchers will assess safety, blood characteristics, and vaso-occlusive crisis events. The study includes careful monitoring of adverse events and blood tests, with a total participation period that may last up to two years for those in the extension phase.
Actively Recruiting
Researchers are evaluating etavopivat, a new oral medicine being developed for blood disorders such as sickle cell disease and thalassaemia. These inherited conditions affect hemoglobin, the protein responsible for carrying oxygen in the body. This long-term study aims to assess the safety and effectiveness of etavopivat treatment over a period of up to 264 weeks, or until the drug is approved in the participants country. Participants will receive one of several oral doses of etavopivat, with dosing adjusted by age those 12 years and older will receive Etavopivat A or C, while children younger than 12 years will receive Etavopivat B. The study involves multiple groups including adults, adolescents, and children with different types of sickle cell disease or thalassaemia. All participants have completed a prior etavopivat treatment study and are continuing treatment in this rollover study. During the study, participants will be regularly monitored for treatment-related side effects and clinical benefits. Researchers will track adverse events, blood crisis rates, hemoglobin levels, hospitalizations, and blood transfusion needs. The study includes long-term safety and efficacy assessments conducted over several years, with monitoring continuing until study completion or drug approval. Participants health and treatment responses will be carefully followed throughout this extended period.
Actively Recruiting
Healthy Volunteer
Researchers are investigating new medicines to prevent Human Immunodeficiency Virus Type 1 HIV-1 infection, focusing on women aged 16 to 30 years who are at risk. The study aims to compare the effectiveness and safety of taking MK-8527 once a month against a standard daily pre-exposure prophylaxis PrEP regimen. This phase 3 trial is designed to evaluate if MK-8527 can better prevent HIV-1 infection and how well participants tolerate this medication. Participants will be randomly assigned to one of two groups. One group will take 11 mg of MK-8527 once monthly and a daily placebo matching the standard PrEP medication. The other group will take the daily standard PrEP drugs Emtricitabinetenofovir disoproxil FTCTDF and a monthly placebo matching MK-8527, both for up to approximately two years. After this period, all participants will receive open-label FTCTDF daily for an additional 28 days. During the study, participants will undergo regular monitoring to track new HIV-1 infections, any adverse events, and reasons for discontinuing the study drug due to side effects. The safety and tolerability of MK-8527 will be assessed over the approximately two-year treatment period. The research team will collect data on these outcomes to understand the benefits and risks of MK-8527 as a preventive option for HIV-1 infection.
Actively Recruiting
Researchers are evaluating etavopivat in adolescents and adults with sickle cell disease to see if it can reduce vaso-occlusive crises painful blockages in blood vessels and protect organs from damage. This phase 3 study will also assess whether etavopivat improves exercise tolerance and reduces fatigue compared to a placebo. The trial is randomized, double-blind, and placebo-controlled to ensure unbiased results on the medications effects. Participants will be randomly assigned to receive either oral etavopivat or a matching placebo. The study treatment is taken by mouth, and participants will be followed closely for about 2 years. This includes monitoring during the treatment period and ongoing assessments to evaluate the drugs impact on sickle cell disease symptoms and related health measures. Throughout the study, participants will undergo evaluations such as blood tests to measure hemoglobin and other markers, 6-minute walking tests to assess exercise capacity, and fatigue questionnaires. Researchers will track the number of vaso-occlusive crises requiring medical contact over 52 weeks as the primary outcome. Safety and efficacy will be monitored regularly, with follow-up continuing until the study ends approximately 4 years after enrollment begins.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of inavolisib combined with Phesgo compared to placebo with Phesgo as maintenance treatment after initial therapy in people with untreated HER2-positive advanced breast cancer that has a PIK3CA mutation. This phase III trial focuses on how well the treatments control the disease and their side effects. Participants first receive induction therapy with Phesgo plus taxane-based chemotherapy. Afterward, they receive maintenance therapy with either inavolisib plus Phesgo or placebo plus Phesgo in 21-day cycles. Phesgo is given by subcutaneous injection every 3 weeks, while inavolisib or placebo tablets are taken daily on days 1 to 21 of each cycle. Optional endocrine therapy may also be provided according to standard care. During the study, participants undergo regular assessments including tumor evaluations, heart function tests, laboratory tests, and quality of life questionnaires. Researchers monitor progression-free survival up to about 40 months and overall survival and other outcomes up to approximately 111 months. Participants are followed closely for adverse events and drug levels. The total study duration may extend up to nearly 10 years, with visits scheduled throughout treatment and follow-up periods.
Actively Recruiting
Healthy Volunteer
This research aims to evaluate a multi-component care strategy called DADA LINK to improve cervical cancer screening and treatment connection among women aged 25 to 49 years in Kenya. The highest rates of cervical cancer occur in sub-Saharan Africa, with it being the leading cause of cancer death among Kenyan women. This study focuses on overcoming barriers at the patient, provider, and facility levels by using tailored strategies based on earlier research and clinic assessments in Nairobi County. The trial compares clinics using the DADA LINK integrated care package, which includes HPV self-sampling kits, care navigation by trained non-physician staff, and use of a mobile health platform called WEMA, against clinics continuing usual care practices. Care coordinators at intervention clinics motivate staff to follow cervical cancer care guidelines, collect patient exit survey data, and manage screening and treatment tracking through the WEMA app. The study lasts 12 months, with an additional 6-month follow-up to assess costs and maintenance of the care strategies. Participants cervical cancer screening and treatment data will be collected from clinic records by study staff. Researchers will measure how many women complete screening during clinic visits and how many receive follow-up triage or treatment within 12 months. The WEMA system also supports communication with patients via text messages to improve attendance. This comprehensive monitoring aims to assess both the implementation and effectiveness of the care package over the study period.
Actively Recruiting
Researchers are evaluating a novel text-based tobacco cessation and education program called Text2Quit-Kenya in patients who use tobacco and visit the Emergency Department ED at Kenyatta National Hospital. This study aims to increase knowledge about tobacco harms and support quitting through mobile health mHealth technology. It uses a mixed-methods approach to assess the implementation and effectiveness of the intervention, which could inform future larger trials in Kenya and contribute to global tobacco cessation efforts. Participants are randomly assigned to receive either the Text2Quit-Kenya intervention or standard care. The Text2Quit-Kenya program delivers automated, interactive text messages timed around a users quit date, encouraging tracking of smoking behaviors and cravings. The study focuses on adapting the tool to the Kenyan context, testing its acceptability, feasibility, and efficacy over a 6-month period. During the study, participants complete surveys and exhaled carbon monoxide tests at baseline and follow-up visits at 1 and 6 months to measure tobacco cessation outcomes. Researchers also collect data on message engagement, tobacco knowledge, cessation attempts, and implementation factors. Participants are monitored for enrollment rates, barriers, facilitators, and cost. The total study duration extends up to 6 months with regular assessments to evaluate how well the text-based intervention supports quitting tobacco.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of the OSPrTTHc cholera conjugate vaccine CCV with and without an alum adjuvant in adults and children living in cholera-prone areas. This phase II randomized controlled study aims to find the best dosing schedule and formulation for CCV in different age groups. The trial includes participants aged 1 to 45 years and compares effects of single and two-dose regimens of the vaccine, including a placebo group and an active comparator group using Euvichol4-Plus, an oral cholera vaccine. The study divides 390 participants into three age groups adults 18-45 years, older children 5-17 years, and younger children 1-4 years. Each group is randomized to receive various combinations of the CCV vaccine with or without alum, placebo injections, or Euvichol4-Plus oral doses. Vaccinations are given by intramuscular injection or orally, with doses spaced either 2 weeks or 6 months apart depending on the group. Safety data is reviewed after each cohort before younger groups begin vaccination to ensure study safety. Participants will have blood samples taken to measure antibody responses against cholera bacteria before and after vaccination, assessing immune reaction at 28 days post first and second doses. Researchers will track adverse events shortly after each dose and throughout the study, which lasts approximately six months. The study will monitor serious side effects, immune response levels, and other health indicators to guide future vaccine use in cholera-endemic regions.
Actively Recruiting
Healthy Volunteer
This research aims to evaluate whether an agricultural intervention can reduce food scarcity and improve health outcomes among pregnant women and their infants in sub-Saharan Africa. The study focuses on 410 pregnant women, half living with HIV, enrolled between 9 and 20 weeks of pregnancy. It seeks to understand how sustainable farming skills and resources might enhance maternal and infant health, socioeconomic status, and behavior during pregnancy and up to 12 months after birth. Participants are randomly assigned to either receive the agricultural intervention immediately or to receive it after the study concludes. The intervention includes providing agricultural supplies such as irrigation pumps, seeds, and fertilizers, along with training in agriculture, agribusiness, and safety. A model farm is also used for training and to supply vegetables until participants farms begin producing. Control participants receive the full intervention after study follow-up. During the study, women will be monitored through clinical and physical measurements at multiple time points 30 and 36 weeks gestation, delivery, and 6 weeks, 3, 6, 9, and 12 months postpartum. Researchers will assess infant length, birth weight, household food insecurity, depression, infant stunting, and empowerment measures. The study includes follow-up for one year after birth to evaluate the interventions impact on health and nutrition.
Actively Recruiting
Tuberculosis TB remains a major global health challenge, especially in regions like Africa where the incidence is high. Extrapulmonary TB EPTB accounts for a significant portion of cases, particularly in areas with high HIV rates. Current diagnostic methods often struggle to detect EPTB due to the low number of bacteria present, which leads to delays or missed diagnoses and increases risks for affected patients. This study focuses on improving diagnosis and treatment monitoring for EPTB using biomarker-based methods in Nairobi, Kenya. The study will use biomarkers such as lipoarabinomannan LAM, MPT64, and Ag85B to develop more sensitive, non-invasive diagnostic tests. Techniques like ultrasensitive enzyme-linked immunosorbent assays ELISA and urine concentration methods will be employed to enhance detection accuracy. The study will enroll 763 adult patients suspected of having EPTB along with 150 control participants. For confirmed EPTB cases, follow-up samples will be collected during treatment to observe biomarker changes and treatment progress. Participants will provide clinical and demographic information along with sputum, blood, and urine samples at enrollment. These samples will be tested to assess the accuracy of the biomarkers compared to standard diagnostic methods. For those with confirmed EPTB, additional samples will be collected during treatment to monitor responses. The study aims to produce diagnostic tools suitable for resource-limited settings and to clarify the presence of non-tuberculosis mycobacteria and fungal infections, helping to guide better patient care in high-burden areas.
1-10 of 39
1